Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 7,227 | 6,174 | 6,471 | 5,602 | 145 |
| Receivables | N/A | N/A | N/A | 7 | N/A |
| Inventories | 590 | 113 | 59 | 192 | 40 |
| Other current assets | 0 | 131 | 273 | 14 | 11 |
| TOTAL | $8,208 | $6,535 | $6,950 | $5,882 | $196 |
| Non-Current Assets | |||||
| PPE Net | 212 | 236 | 273 | 242 | 295 |
| Other Non-Current Assets | 345 | 405 | 0 | 0 | 0 |
| TOTAL | $557 | $641 | $273 | $242 | $295 |
| Total Assets | $8,765 | $7,176 | $7,223 | $6,124 | $491 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 910 | 1,709 | 975 | 848 | 435 |
| TOTAL | $987 | $2,073 | $975 | $848 | $1,385 |
| Non-Current Liabilities | |||||
| Long Term Debt | 337 | N/A | N/A | N/A | N/A |
| Other Non-Current Liabilities | 272 | 343 | 0 | 0 | 0 |
| TOTAL | $609 | $343 | $N/A | $N/A | $N/A |
| Total Liabilities | $1,596 | $2,416 | $975 | $848 | $1,385 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1 | 0 | 0 | 0 | N/A |
| Common Shares | 3 | 1 | 1 | 0 | 0 |
| Retained earnings | -57,339 | -45,217 | -27,692 | -17,895 | -12,519 |
| Other shareholders' equity | 11 | 44 | 0 | 0 | 81 |
| TOTAL | $7,169 | $4,761 | $6,248 | $5,276 | $-894 |
| Total Liabilities And Equity | $8,765 | $7,176 | $7,223 | $6,124 | $491 |